Showing results (191-200 of 242) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 TrialPaul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.Lancet (London, England)|March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trialJonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialPaul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.Gynecologic Oncology|May 31, 2024
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and overOmali Pitiyarachchi, Peter J Ansell, Robert L Coleman, et al.Gynecologic Oncology|August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trialSusana N Banerjee, Monica Tang, Rachel L O'Connell, et al.Gynecologic Oncology|January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 studyPhilipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancerSharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.The Lancet. Oncology|August 31, 2020
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialVéronique Diéras, Hyo S Han, Bella Kaufman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2011
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancerMichael S Anglesio, Joshy George, Hagen Kulbe, et al.The Lancet. Oncology|April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trialMichael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.Pageof 25